May 24, 2019 07:32 AM EDT

Novocure bags mesothelioma nod for electric fields cancer therapy with some limitations

Amber Tong

Novocure has secured the FDA’s blessing for another use of its tumor treating fields: malignant pleural mesothelioma, a rare cancer that develops in the linings …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novocure bags mesothelioma nod for electric fields cancer therapy with some limitations

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Novocure bags mesothelioma nod for electric fields cancer therapy with some limitations

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months